RxDoctor Payments Data

Marshall Long, DO

Family Medicine · Princeton, WVNPI 1487718672

Payments from drug & device makers

$820in general payments, 2019–2025

Across 18 payments — averaging $45.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$164
  • Alnylam Pharmaceuticals Inc.$109
  • Lilly USA, LLC$101
  • Amgen$95
  • Novartis$93
  • Novo Nordisk$72
  • plus $186 from 5 others

What the payments were for

  • Food & beverage$820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$820 in reported general payments places this provider in the 65th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$104,906
Medicare patients
235
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin183$262,870
EliquisApixaban182$226,245
OzempicSemaglutide118$181,083
RybelsusSemaglutide61$86,091
MounjaroTirzepatide44$62,445
TrulicityDulaglutide41$62,290
LinzessLinaclotide52$57,085
JanuviaSitagliptin Phosphate29$47,320
FarxigaDapagliflozin Propanediol18$30,098
TradjentaLinagliptin22$26,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,874
GlyxambiEmpagliflozin/Linagliptin16$26,482
Janumet XrSitagliptin Phos/Metformin Hcl11$18,807
SymbicortBudesonide/Formoterol Fumarate52$18,167
MyrbetriqMirabegron19$17,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$55$316,239221 claims
Novo NordiskOzempic, Rybelsus$72$267,173179 claims
Lilly USA, LLCMounjaro, Trulicity$101$124,73585 claims
MerckJanuvia, Janumet Xr, Janumet$13$81,77253 claims
AstraZenecaFarxiga, Symbicort$44$48,26570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Princeton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →